论文部分内容阅读
深入研究活血化瘀中药８６１合剂的抗纤雏化机理。方法将２４只雄性Ｗｉｓｔａｒ大鼠随机分为正常对照组，人血白蛋白免疫损伤性肝纤雏化病理模型组及中药８６１合剂预防组。在用药２．５及５个月时取肝脏组织做病理学、免疫组化及斑点杂交。结果与病理模型组相比，８６１预防组大鼠肝脏纤维化分级明显减轻，肝脏Ⅰ、Ⅲ、Ⅳ型脐原面积比减小，Ⅰ、Ⅲ、Ⅳ型胶原及ＴＧＦ－βｍＲＮＡ水平明显降低（Ｐ值＜０．０５）。结论中药８６１合剂的抗人血白蛋白免疫损伤性大鼠肝纤维化机理之一可能是抑制了肝脏Ⅰ、Ⅲ．Ⅳ型胶原和ＴＧＦ－β的基因表达。
In-depth study of anti-fibrosis mechanism of Chinese medicine 861 mixture of Huoxue Huayu. Methods Twenty-four male Wistar rats were randomly divided into normal control group, human serum albumin immunostative pathological model of liver fibrosis and Chinese medicine 861 mixture prevention group. At 2.5 and 5 months after treatment, the liver tissues were taken for pathology, immunohistochemistry and dot blot hybridization. Results Compared with the pathological model group, the fibrosis grade of the rats in the 861-treated group was significantly reduced, the area ratio of the umbilical cords of type Ⅰ, Ⅲ and Ⅳ decreased, and the levels of collagen type Ⅰ, Ⅲ, Ⅳ and TGF-βmRNA decreased significantly Value <0.05). Conclusion One of the mechanisms of anti-serum albumin immunocompromised rat liver fibrosis is 861 mixture, which may inhibit the liver Ⅰ, Ⅲ. Type IV collagen and TGF-β gene expression.